►Upon simple mixing of PEG and αCD, the hydrophobic repeating segments of PEG spontaneously thread into the hydrophobic inner cavity of αCD, generating strong supramolecular interactions that drive physical self-assembly. We refer to this distinctive self-assembly principle as the "Glide-in" mechanism. 

►Upon simple mixing of αCD-conjugated HA with PEG, the repeating units of PEG thread through the inner cavities of αCD via the Glide-in mechanism, creating a hydrogel network through physical self-assembly without covalent crosslinking. We term this locally injectable platform Glide-in HydroMatrix™ (GHM). 

►GHM is designed to provide key technological advantages, including local injectability, drug-loading capability, controlled release, biodegradability, easily tunable viscoelasticity, and in vivo safety. 

►Upon simple mixing of an αCD-conjugated API with PEG, the repeating units of PEG thread through the inner cavities of αCD via the Glide-in mechanism, enabling PEGylation through physical self-assembly rather than covalent chemistry. We term this systemic-circulation platform Glide-in PEGylation™ (GPP). 

►GPP is a next-generation PEGylation 2.0 drug formulation platform that replaces conventional chemical PEGylation processes with a simple physical mixing approach. Designed for APIs with extracellular mechanisms of action, GPP also features a differentiated structural design intended to help reduce potential Anti-PEG Antibody (APA) concerns. 

►Tier 1. The IMD Group comprises OcuHydra-CS™, a prescription therapy for dry eye disease; OcuThera-V™, a depot-based glaucoma treatment; and Inflexa™, a therapeutic for arthritis pain relief. All three IMD assets are based on the shared GHM platform.

►Tier 2. The GPP-T Series is a systemic drug formulation platform built on next-generation PEGylation 2.0 technology for APIs with extracellular mechanisms of action.

►Both platform technologies are designed to advance rapidly through the pre-FIH stage, with a development roadmap focused on early-stage licensing-out and technology transfer.

• Head Office: #204, Building V1, KIST, 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul, Republic of Korea

• Business Registration No. 611-81-30865 

• Date of Incorporation: March 18, 2026 

• email: chryse@glide-in.com

• IR Biz Channel(KOR): http://pf.kakao.com/_JxdICX 

For further information on our development technologies, business activities, sector-specific partnerships, or IR materials, please contact GlideLink via email. 

TBD